← SynDRA
CANTHARIDIN
SynDRA canonical compound SYN0002331 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | protein phosphatase inhibitor |
|---|
| Indication | blisters |
|---|
| Disease area | dermatology |
|---|
All known targets
Mechanisms of action (all sources)
- protein phosphatase inhibitor
- PPP1CA INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PPM1B
- TFPI2
- PPP1CC
- PPP2CA
- PPP5C
- PTPN1
- MC3R
- NR3C1
- NPY4R
- NPY2R
- NPY1R
- MMP9
- MMP1
- MC5R
- MC4R
- MAPK3
- OPRK1
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- KCNH2
- KAT2A
- HTR6
- HTR2C
- HTR2B
- HTR2A
- OPRD1
- ACHE
- OPRM1
- SLC6A3
- TRIP13
- TP53
- TBXAS1
- TACR2
- TACR1
- SMN1
- SLCO1B3
- SLCO1B1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- GCR
- HLAB
- IFNB1
- KSYK
- MK01
- NSD2
- SYK
Drug classes
- Enzyme Inhibitors
- Irritants
- Noxae
Cross-references
Synonyms
- YCANTH
- Ycanth
- ycanth
- Cantaridina
- Cantharides camphor
- Cantharidine
- Cantharidinum
- NSC-61805
- DSSTox_CID_21752
- DSSTox_RID_79835
- DSSTox_GSID_41752
- CAS-56-25-7
- NCGC00016247-01
- Spectrum_001114
- SpecPlus_000537
- Spectrum4_000920
- Spectrum2_000630
- Prestwick0_000885
- Spectrum3_000621
- Prestwick1_000885
- Spectrum5_001618
- Prestwick2_000885
- KBioSS_001594
- KBioGR_001420
- BSPBio_002182
- MLS002153505
- SCHEMBL152261
- DivK1c_006633
- SPBio_002889
- SPBio_000600
- CHEMBL299846
- DTXSID7041752
- KBio2_006730
- KBio3_001682
- KBio2_004162
- KBio2_001594
- KBio1_001577
- MolPort-003-665-556
Reported adverse events
- Application site erythema
- Application site pain
- Application site pruritus
- Application site vesicles
- Application site dryness
- Application site erosion
- Application site scab
Look up CANTHARIDIN in the interactive SynDRA portal →